MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm14144900

Медицинская библиотека · Journal of clinical medicine · 2025

Efficacy of Aflibercept 8 mg in Pretreated Age-Related Macular Degeneration.

Palm Christiane, Zweifel Sandrine Anne, Gabathuler Felix, Cozzi Mariano, Fasler Katrin

СтатьяПеревод пока не подготовлен

Аннотация

This study aims to evaluate the real-world efficacy and safety of aflibercept 8 mg intravitreal injections (IVTs) in pretreated patients with neovascular age-related macular degeneration (nAMD) throughout the first three IVTs.

Background

Established anti-vascular-endothelial-growth-factor (anti-VEGF) therapies positively impact the progression of nAMD but require frequent administration, thus burdening patients and the healthcare system. Pivotal trials of the recently approved aflibercept 8 mg have demonstrated extended dosing intervals with comparable safety to standard treatments. However, real-world data is still scarce.

Methods

A retrospective, single-center single-arm analysis was conducted on 22 eyes from 18 pretreated nAMD patients. Eyes were switched from other anti-VEGF agents to aflibercept 8 mg injections continuing a treat-and-extend regimen (no loading dose after switching). Treatment intervals and structural (central subfield thickness (CST); disease activity) and functional (best corrected visual acuity (BCVA)) outcomes were assessed at baseline (date of first aflibercept 8 mg injection) and at follow-up examinations until follow-up 3. Safety data, including intraocular pressure changes, were recorded.

Results

Over a median follow-up of 16.6 weeks (IQR 15.1-27.0), patients switched to aflibercept 8 mg showed prolonged intervals between injections (5.5 weeks vs. 7 weeks, p < 0.001, Wilcoxon signed-rank test), reduced disease activity, stable CST, and stable BCVA. One patient experienced transient intraocular pressure elevation, which resolved without intervention. No other adverse events were observed.

Conclusions

Treatment with aflibercept 8 mg appears to provide effective disease control with prolonged treatment intervals in switched nAMD patients in routine clinical practice. These findings further indicate the potential for reducing treatment burden.

Для цитирования: Palm Christiane, Zweifel Sandrine Anne, Gabathuler Felix, Cozzi Mariano, Fasler Katrin. Efficacy of Aflibercept 8 mg in Pretreated Age-Related Macular Degeneration.. Journal of clinical medicine. 2025. DOI: 10.3390/jcm14144900.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.